Glencoe Regional Health Services | |
1805 Hennepin Avenue North, Glencoe, Minnesota 55336 | |
(320) 864-3121 | |
Name | Glencoe Regional Health Services |
---|---|
Location | 1805 Hennepin Avenue North, Glencoe, Minnesota |
Certified By | Medicare and Medicaid |
No. of Certified Beds | 99 |
Occupancy Rate | 89.39% |
Medicare ID (CCN) | 245263 |
Legal Business Name | Glencoe Regional Health Services |
Ownership Type | Non Profit - Corporation |
NPI Number | 1972610079 |
Organization Name | GLENCOE REGIONAL HEALTH SERVICES |
Address | 1805 Hennepin Ave N, Glencoe, MN 55336 |
Phone Number | 320-864-7790 |
News Archive
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
Questions regarding effectiveness, infrastructure and cost effectiveness of low-dose computed tomography (CT) screening of those at high risk for lung cancer have now been answered. Medicare should rapidly provide full national coverage for these exams.
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
A new gene therapy for one of the most common forms of congenital blindness was safe and improved patients' vision, according to initial data from a clinical trial led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.
Scientists from the University of Sheffield and University of Manchester have been awarded £265,000 from the British Heart Foundation, to investigate the links between vascular dementia and heart disease, and test whether a drug currently used to treat arthritis could also be used as a treatment for vascular dementia.
› Verified 5 days ago
Ratings from Surveys (Inspections): | |
Ratings from Quality Measures: | |
Ratings from Staffing Data: | |
Overall Rating: |
---|
News Archive
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
Questions regarding effectiveness, infrastructure and cost effectiveness of low-dose computed tomography (CT) screening of those at high risk for lung cancer have now been answered. Medicare should rapidly provide full national coverage for these exams.
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
A new gene therapy for one of the most common forms of congenital blindness was safe and improved patients' vision, according to initial data from a clinical trial led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.
Scientists from the University of Sheffield and University of Manchester have been awarded £265,000 from the British Heart Foundation, to investigate the links between vascular dementia and heart disease, and test whether a drug currently used to treat arthritis could also be used as a treatment for vascular dementia.
› Verified 5 days ago
Number of Facility Reported Incidents | 0 |
Number of Substantiated Complaints | 0 |
Number of Fines | 0 |
Total Amount of Fines in Dollars | $0 |
Number of Payment Denials | 0 |
Total Number of Penalties | 0 |
Experience Measure | Provider | National Avg. |
---|---|---|
Percentage of long-stay residents whose need for help with daily activities has increased | 12.12 | 14.46 |
Percentage of long-stay residents who lose too much weight | 11.04 | 5.51 |
Percentage of low risk long-stay residents who lose control of their bowels or bladder | 44.97 | 48.41 |
Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.13 | 1.79 |
Percentage of long-stay residents with a urinary tract infection | 3.15 | 2.65 |
Percentage of long-stay residents who have depressive symptoms | 0 | 5.05 |
Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
Percentage of long-stay residents experiencing one or more falls with major injury | 4.67 | 3.36 |
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.38 | 93.87 |
Percentage of long-stay residents who received an antipsychotic medication | 16.77 | 14.2 |
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 96.8 | 83.88 |
Percentage of short-stay residents who newly received an antipsychotic medication | 1.48 | 1.79 |
Percentage of long-stay residents whose ability to move independently worsened | 14.59 | 17.09 |
Percentage of long-stay residents who received an antianxiety or hypnotic medication | 8.28 | 19.7 |
Percentage of high risk long-stay residents with pressure ulcers | 2.69 | 7.32 |
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |
Percentage of short-stay residents who made improvements in function | 74.7 | 67.99 |
Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 91.25 | 82.93 |
News Archive
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
Questions regarding effectiveness, infrastructure and cost effectiveness of low-dose computed tomography (CT) screening of those at high risk for lung cancer have now been answered. Medicare should rapidly provide full national coverage for these exams.
A Brazilian study shows that inhibition of an RNA named RMEL3, which is encoded by a previously uncharacterized gene (also named RMEL3), can reduce the viability of cultured melanoma cells by up to 95%.
A new gene therapy for one of the most common forms of congenital blindness was safe and improved patients' vision, according to initial data from a clinical trial led by researchers at the Scheie Eye Institute in the Perelman School of Medicine at the University of Pennsylvania.
Scientists from the University of Sheffield and University of Manchester have been awarded £265,000 from the British Heart Foundation, to investigate the links between vascular dementia and heart disease, and test whether a drug currently used to treat arthritis could also be used as a treatment for vascular dementia.
› Verified 5 days ago
Glencoe Regional Health Services Location: 1805 Hennepin Avenue North, Glencoe, Minnesota 55336 Phone: (320) 864-3121 |